Publications by authors named "Roderick Porter"

Claim this Profile
D
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.
David Harrison, Andy Billinton, Mark G Bock, John R Doedens, Christopher A Gabel, Roderick A Porter

J Med Chem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure-Activity Relationships and Optimization.
Jean-Olivier Zirimwabagabo, Ameera B A Jailani, Paris Avgoustou, Matthew J Tozer, Karl R Gibson, Roderick A Porter

J Med Chem· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors.
David Harrison, Nicolas Boutard, Krzysztof Brzozka, Marta Bugaj, Stefan Chmielewski, Roderick A Porter

Bioorg Med Chem Lett· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor.
Paris Avgoustou, Ameera B A Jailani, Jean-Olivier Zirimwabagabo, Matthew J Tozer, Karl R Gibson, Roderick A Porter

ACS Pharmacol Transl Sci· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Malini Menon, Richard Elliott, Leandra Bowers, Nicolae Balan, Rumana Rafiq, Roderick Porter

Sci Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
Lee A Dawson, Roderick A Porter

Future Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acylglycinamides as inhibitors of glycine transporter type 1.
Richard Blunt, Roderick Porter, Amanda Johns, David Nash, Gemma Puckey

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1.
Shahzad S Rahman, Steven Coulton, Hugh J Herdon, Graham F Joiner, Jian Jin, Roderick A Porter

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis